| Northeastern Eye Institute | |
|
200 Mifflin Ave, Scranton, PA 18503 | |
| (570) 342-3145 | |
| Not Available |
| Full Name | Northeastern Eye Institute |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 200 Mifflin Ave, Scranton, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366554172 | NPI | - | NPPES |
| 44005758 | Other | PA | HIGHMARK BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | (* (Not Available)) | Primary |
| Provider Name | Thomas Stanley Boland |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1174635924 PECOS PAC ID: 0547164451 Enrollment ID: I20031121000804 |
News Archive
Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.
Neovasc Inc. is pleased to announce the closing of its previously announced underwritten public offering of 12,075,000 common shares of the Company at a price per share of US$7.19 (the "Offering") for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the Selling Securityholders (as defined below) before deducting underwriting discounts and commissions and offering expenses payable by the Company and the Selling Securityholders.
A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.
A new study that appeared last Friday in British Medical Journal showed that one in three adults aged over 65 in England have difficulty understanding basic health-related information. They are more than twice as likely to die within five years as adults with no literacy problems, it was found.
With the help of 14 satellites currently in orbit and the National Aeronautics and Space Administration's (NASA) Applied Sciences Program, scientists have been able to observe the Earth's environment to help predict and prevent infectious disease outbreaks around the world.
› Verified 6 days ago
| Provider Name | Cynthia G Charnetski |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1457463275 PECOS PAC ID: 5698763654 Enrollment ID: I20040506000412 |
News Archive
Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.
Neovasc Inc. is pleased to announce the closing of its previously announced underwritten public offering of 12,075,000 common shares of the Company at a price per share of US$7.19 (the "Offering") for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the Selling Securityholders (as defined below) before deducting underwriting discounts and commissions and offering expenses payable by the Company and the Selling Securityholders.
A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.
A new study that appeared last Friday in British Medical Journal showed that one in three adults aged over 65 in England have difficulty understanding basic health-related information. They are more than twice as likely to die within five years as adults with no literacy problems, it was found.
With the help of 14 satellites currently in orbit and the National Aeronautics and Space Administration's (NASA) Applied Sciences Program, scientists have been able to observe the Earth's environment to help predict and prevent infectious disease outbreaks around the world.
› Verified 6 days ago
| Provider Name | Maryellen Judge |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1124012471 PECOS PAC ID: 4385698950 Enrollment ID: I20050307000342 |
News Archive
Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.
Neovasc Inc. is pleased to announce the closing of its previously announced underwritten public offering of 12,075,000 common shares of the Company at a price per share of US$7.19 (the "Offering") for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the Selling Securityholders (as defined below) before deducting underwriting discounts and commissions and offering expenses payable by the Company and the Selling Securityholders.
A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.
A new study that appeared last Friday in British Medical Journal showed that one in three adults aged over 65 in England have difficulty understanding basic health-related information. They are more than twice as likely to die within five years as adults with no literacy problems, it was found.
With the help of 14 satellites currently in orbit and the National Aeronautics and Space Administration's (NASA) Applied Sciences Program, scientists have been able to observe the Earth's environment to help predict and prevent infectious disease outbreaks around the world.
› Verified 6 days ago
| Provider Name | Jerard W Brown |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1376539916 PECOS PAC ID: 4082653118 Enrollment ID: I20050428000473 |
News Archive
Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.
Neovasc Inc. is pleased to announce the closing of its previously announced underwritten public offering of 12,075,000 common shares of the Company at a price per share of US$7.19 (the "Offering") for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the Selling Securityholders (as defined below) before deducting underwriting discounts and commissions and offering expenses payable by the Company and the Selling Securityholders.
A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.
A new study that appeared last Friday in British Medical Journal showed that one in three adults aged over 65 in England have difficulty understanding basic health-related information. They are more than twice as likely to die within five years as adults with no literacy problems, it was found.
With the help of 14 satellites currently in orbit and the National Aeronautics and Space Administration's (NASA) Applied Sciences Program, scientists have been able to observe the Earth's environment to help predict and prevent infectious disease outbreaks around the world.
› Verified 6 days ago
| Provider Name | Melanie Ann Brown-demichele |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1972615722 PECOS PAC ID: 1951341817 Enrollment ID: I20050510000715 |
News Archive
Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.
Neovasc Inc. is pleased to announce the closing of its previously announced underwritten public offering of 12,075,000 common shares of the Company at a price per share of US$7.19 (the "Offering") for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the Selling Securityholders (as defined below) before deducting underwriting discounts and commissions and offering expenses payable by the Company and the Selling Securityholders.
A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.
A new study that appeared last Friday in British Medical Journal showed that one in three adults aged over 65 in England have difficulty understanding basic health-related information. They are more than twice as likely to die within five years as adults with no literacy problems, it was found.
With the help of 14 satellites currently in orbit and the National Aeronautics and Space Administration's (NASA) Applied Sciences Program, scientists have been able to observe the Earth's environment to help predict and prevent infectious disease outbreaks around the world.
› Verified 6 days ago
| Provider Name | Michael Robert Boland |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1962414078 PECOS PAC ID: 8123062619 Enrollment ID: I20050615000635 |
News Archive
Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.
Neovasc Inc. is pleased to announce the closing of its previously announced underwritten public offering of 12,075,000 common shares of the Company at a price per share of US$7.19 (the "Offering") for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the Selling Securityholders (as defined below) before deducting underwriting discounts and commissions and offering expenses payable by the Company and the Selling Securityholders.
A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.
A new study that appeared last Friday in British Medical Journal showed that one in three adults aged over 65 in England have difficulty understanding basic health-related information. They are more than twice as likely to die within five years as adults with no literacy problems, it was found.
With the help of 14 satellites currently in orbit and the National Aeronautics and Space Administration's (NASA) Applied Sciences Program, scientists have been able to observe the Earth's environment to help predict and prevent infectious disease outbreaks around the world.
› Verified 6 days ago
| Provider Name | Carlene Ann Siracuse |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1639275696 PECOS PAC ID: 1557362613 Enrollment ID: I20070117000060 |
News Archive
Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.
Neovasc Inc. is pleased to announce the closing of its previously announced underwritten public offering of 12,075,000 common shares of the Company at a price per share of US$7.19 (the "Offering") for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the Selling Securityholders (as defined below) before deducting underwriting discounts and commissions and offering expenses payable by the Company and the Selling Securityholders.
A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.
A new study that appeared last Friday in British Medical Journal showed that one in three adults aged over 65 in England have difficulty understanding basic health-related information. They are more than twice as likely to die within five years as adults with no literacy problems, it was found.
With the help of 14 satellites currently in orbit and the National Aeronautics and Space Administration's (NASA) Applied Sciences Program, scientists have been able to observe the Earth's environment to help predict and prevent infectious disease outbreaks around the world.
› Verified 6 days ago
| Provider Name | Lindsey Connors Kelly |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1750589818 PECOS PAC ID: 5294829404 Enrollment ID: I20070919000419 |
News Archive
Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.
Neovasc Inc. is pleased to announce the closing of its previously announced underwritten public offering of 12,075,000 common shares of the Company at a price per share of US$7.19 (the "Offering") for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the Selling Securityholders (as defined below) before deducting underwriting discounts and commissions and offering expenses payable by the Company and the Selling Securityholders.
A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.
A new study that appeared last Friday in British Medical Journal showed that one in three adults aged over 65 in England have difficulty understanding basic health-related information. They are more than twice as likely to die within five years as adults with no literacy problems, it was found.
With the help of 14 satellites currently in orbit and the National Aeronautics and Space Administration's (NASA) Applied Sciences Program, scientists have been able to observe the Earth's environment to help predict and prevent infectious disease outbreaks around the world.
› Verified 6 days ago
| Provider Name | Christopher S Jordan |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1053362574 PECOS PAC ID: 2466452453 Enrollment ID: I20071015000041 |
News Archive
Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.
Neovasc Inc. is pleased to announce the closing of its previously announced underwritten public offering of 12,075,000 common shares of the Company at a price per share of US$7.19 (the "Offering") for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the Selling Securityholders (as defined below) before deducting underwriting discounts and commissions and offering expenses payable by the Company and the Selling Securityholders.
A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.
A new study that appeared last Friday in British Medical Journal showed that one in three adults aged over 65 in England have difficulty understanding basic health-related information. They are more than twice as likely to die within five years as adults with no literacy problems, it was found.
With the help of 14 satellites currently in orbit and the National Aeronautics and Space Administration's (NASA) Applied Sciences Program, scientists have been able to observe the Earth's environment to help predict and prevent infectious disease outbreaks around the world.
› Verified 6 days ago
| Provider Name | Lisa A Toole |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1346234689 PECOS PAC ID: 4688736200 Enrollment ID: I20081216000404 |
News Archive
Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.
Neovasc Inc. is pleased to announce the closing of its previously announced underwritten public offering of 12,075,000 common shares of the Company at a price per share of US$7.19 (the "Offering") for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the Selling Securityholders (as defined below) before deducting underwriting discounts and commissions and offering expenses payable by the Company and the Selling Securityholders.
A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.
A new study that appeared last Friday in British Medical Journal showed that one in three adults aged over 65 in England have difficulty understanding basic health-related information. They are more than twice as likely to die within five years as adults with no literacy problems, it was found.
With the help of 14 satellites currently in orbit and the National Aeronautics and Space Administration's (NASA) Applied Sciences Program, scientists have been able to observe the Earth's environment to help predict and prevent infectious disease outbreaks around the world.
› Verified 6 days ago
| Provider Name | Megan M Walsh |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1114180783 PECOS PAC ID: 3678625332 Enrollment ID: I20090710000431 |
News Archive
Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.
Neovasc Inc. is pleased to announce the closing of its previously announced underwritten public offering of 12,075,000 common shares of the Company at a price per share of US$7.19 (the "Offering") for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the Selling Securityholders (as defined below) before deducting underwriting discounts and commissions and offering expenses payable by the Company and the Selling Securityholders.
A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.
A new study that appeared last Friday in British Medical Journal showed that one in three adults aged over 65 in England have difficulty understanding basic health-related information. They are more than twice as likely to die within five years as adults with no literacy problems, it was found.
With the help of 14 satellites currently in orbit and the National Aeronautics and Space Administration's (NASA) Applied Sciences Program, scientists have been able to observe the Earth's environment to help predict and prevent infectious disease outbreaks around the world.
› Verified 6 days ago
| Provider Name | Mary Frattali |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1447362272 PECOS PAC ID: 9032137815 Enrollment ID: I20100202000004 |
News Archive
Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.
Neovasc Inc. is pleased to announce the closing of its previously announced underwritten public offering of 12,075,000 common shares of the Company at a price per share of US$7.19 (the "Offering") for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the Selling Securityholders (as defined below) before deducting underwriting discounts and commissions and offering expenses payable by the Company and the Selling Securityholders.
A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.
A new study that appeared last Friday in British Medical Journal showed that one in three adults aged over 65 in England have difficulty understanding basic health-related information. They are more than twice as likely to die within five years as adults with no literacy problems, it was found.
With the help of 14 satellites currently in orbit and the National Aeronautics and Space Administration's (NASA) Applied Sciences Program, scientists have been able to observe the Earth's environment to help predict and prevent infectious disease outbreaks around the world.
› Verified 6 days ago
| Provider Name | Arthur Joseph Jordan |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1376655126 PECOS PAC ID: 2466403613 Enrollment ID: I20100202000024 |
News Archive
Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.
Neovasc Inc. is pleased to announce the closing of its previously announced underwritten public offering of 12,075,000 common shares of the Company at a price per share of US$7.19 (the "Offering") for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the Selling Securityholders (as defined below) before deducting underwriting discounts and commissions and offering expenses payable by the Company and the Selling Securityholders.
A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.
A new study that appeared last Friday in British Medical Journal showed that one in three adults aged over 65 in England have difficulty understanding basic health-related information. They are more than twice as likely to die within five years as adults with no literacy problems, it was found.
With the help of 14 satellites currently in orbit and the National Aeronautics and Space Administration's (NASA) Applied Sciences Program, scientists have been able to observe the Earth's environment to help predict and prevent infectious disease outbreaks around the world.
› Verified 6 days ago
| Provider Name | Jerome William Jordan |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1952413791 PECOS PAC ID: 4284538190 Enrollment ID: I20100202000288 |
News Archive
Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.
Neovasc Inc. is pleased to announce the closing of its previously announced underwritten public offering of 12,075,000 common shares of the Company at a price per share of US$7.19 (the "Offering") for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the Selling Securityholders (as defined below) before deducting underwriting discounts and commissions and offering expenses payable by the Company and the Selling Securityholders.
A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.
A new study that appeared last Friday in British Medical Journal showed that one in three adults aged over 65 in England have difficulty understanding basic health-related information. They are more than twice as likely to die within five years as adults with no literacy problems, it was found.
With the help of 14 satellites currently in orbit and the National Aeronautics and Space Administration's (NASA) Applied Sciences Program, scientists have been able to observe the Earth's environment to help predict and prevent infectious disease outbreaks around the world.
› Verified 6 days ago
| Provider Name | William J Jordan |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1922110766 PECOS PAC ID: 3274542865 Enrollment ID: I20100203000674 |
News Archive
Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.
Neovasc Inc. is pleased to announce the closing of its previously announced underwritten public offering of 12,075,000 common shares of the Company at a price per share of US$7.19 (the "Offering") for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the Selling Securityholders (as defined below) before deducting underwriting discounts and commissions and offering expenses payable by the Company and the Selling Securityholders.
A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.
A new study that appeared last Friday in British Medical Journal showed that one in three adults aged over 65 in England have difficulty understanding basic health-related information. They are more than twice as likely to die within five years as adults with no literacy problems, it was found.
With the help of 14 satellites currently in orbit and the National Aeronautics and Space Administration's (NASA) Applied Sciences Program, scientists have been able to observe the Earth's environment to help predict and prevent infectious disease outbreaks around the world.
› Verified 6 days ago
| Provider Name | Mary Elizabeth Jordan Flickinger |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1003828120 PECOS PAC ID: 7416091335 Enrollment ID: I20100216000612 |
News Archive
Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.
Neovasc Inc. is pleased to announce the closing of its previously announced underwritten public offering of 12,075,000 common shares of the Company at a price per share of US$7.19 (the "Offering") for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the Selling Securityholders (as defined below) before deducting underwriting discounts and commissions and offering expenses payable by the Company and the Selling Securityholders.
A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.
A new study that appeared last Friday in British Medical Journal showed that one in three adults aged over 65 in England have difficulty understanding basic health-related information. They are more than twice as likely to die within five years as adults with no literacy problems, it was found.
With the help of 14 satellites currently in orbit and the National Aeronautics and Space Administration's (NASA) Applied Sciences Program, scientists have been able to observe the Earth's environment to help predict and prevent infectious disease outbreaks around the world.
› Verified 6 days ago
| Provider Name | Randall Ray Peairs |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1003918475 PECOS PAC ID: 6406874288 Enrollment ID: I20100217000809 |
News Archive
Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.
Neovasc Inc. is pleased to announce the closing of its previously announced underwritten public offering of 12,075,000 common shares of the Company at a price per share of US$7.19 (the "Offering") for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the Selling Securityholders (as defined below) before deducting underwriting discounts and commissions and offering expenses payable by the Company and the Selling Securityholders.
A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.
A new study that appeared last Friday in British Medical Journal showed that one in three adults aged over 65 in England have difficulty understanding basic health-related information. They are more than twice as likely to die within five years as adults with no literacy problems, it was found.
With the help of 14 satellites currently in orbit and the National Aeronautics and Space Administration's (NASA) Applied Sciences Program, scientists have been able to observe the Earth's environment to help predict and prevent infectious disease outbreaks around the world.
› Verified 6 days ago
| Provider Name | Joseph Patrick Shovlin |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1518970623 PECOS PAC ID: 7012051444 Enrollment ID: I20100223000257 |
News Archive
Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.
Neovasc Inc. is pleased to announce the closing of its previously announced underwritten public offering of 12,075,000 common shares of the Company at a price per share of US$7.19 (the "Offering") for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the Selling Securityholders (as defined below) before deducting underwriting discounts and commissions and offering expenses payable by the Company and the Selling Securityholders.
A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.
A new study that appeared last Friday in British Medical Journal showed that one in three adults aged over 65 in England have difficulty understanding basic health-related information. They are more than twice as likely to die within five years as adults with no literacy problems, it was found.
With the help of 14 satellites currently in orbit and the National Aeronautics and Space Administration's (NASA) Applied Sciences Program, scientists have been able to observe the Earth's environment to help predict and prevent infectious disease outbreaks around the world.
› Verified 6 days ago
| Provider Name | Michael J Rymar |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1700998549 PECOS PAC ID: 2365587581 Enrollment ID: I20100226000453 |
News Archive
Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.
Neovasc Inc. is pleased to announce the closing of its previously announced underwritten public offering of 12,075,000 common shares of the Company at a price per share of US$7.19 (the "Offering") for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the Selling Securityholders (as defined below) before deducting underwriting discounts and commissions and offering expenses payable by the Company and the Selling Securityholders.
A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.
A new study that appeared last Friday in British Medical Journal showed that one in three adults aged over 65 in England have difficulty understanding basic health-related information. They are more than twice as likely to die within five years as adults with no literacy problems, it was found.
With the help of 14 satellites currently in orbit and the National Aeronautics and Space Administration's (NASA) Applied Sciences Program, scientists have been able to observe the Earth's environment to help predict and prevent infectious disease outbreaks around the world.
› Verified 6 days ago
| Provider Name | Barbara Ann Caputo-fox |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1508878612 PECOS PAC ID: 0446395586 Enrollment ID: I20100301000829 |
News Archive
Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.
Neovasc Inc. is pleased to announce the closing of its previously announced underwritten public offering of 12,075,000 common shares of the Company at a price per share of US$7.19 (the "Offering") for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the Selling Securityholders (as defined below) before deducting underwriting discounts and commissions and offering expenses payable by the Company and the Selling Securityholders.
A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.
A new study that appeared last Friday in British Medical Journal showed that one in three adults aged over 65 in England have difficulty understanding basic health-related information. They are more than twice as likely to die within five years as adults with no literacy problems, it was found.
With the help of 14 satellites currently in orbit and the National Aeronautics and Space Administration's (NASA) Applied Sciences Program, scientists have been able to observe the Earth's environment to help predict and prevent infectious disease outbreaks around the world.
› Verified 6 days ago
| Provider Name | Lisa Marie Mongiello |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1548273600 PECOS PAC ID: 6002951928 Enrollment ID: I20100303000732 |
News Archive
Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.
Neovasc Inc. is pleased to announce the closing of its previously announced underwritten public offering of 12,075,000 common shares of the Company at a price per share of US$7.19 (the "Offering") for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the Selling Securityholders (as defined below) before deducting underwriting discounts and commissions and offering expenses payable by the Company and the Selling Securityholders.
A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.
A new study that appeared last Friday in British Medical Journal showed that one in three adults aged over 65 in England have difficulty understanding basic health-related information. They are more than twice as likely to die within five years as adults with no literacy problems, it was found.
With the help of 14 satellites currently in orbit and the National Aeronautics and Space Administration's (NASA) Applied Sciences Program, scientists have been able to observe the Earth's environment to help predict and prevent infectious disease outbreaks around the world.
› Verified 6 days ago
| Provider Name | James B Flickinger |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1184636284 PECOS PAC ID: 8921133836 Enrollment ID: I20100317000726 |
News Archive
Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.
Neovasc Inc. is pleased to announce the closing of its previously announced underwritten public offering of 12,075,000 common shares of the Company at a price per share of US$7.19 (the "Offering") for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the Selling Securityholders (as defined below) before deducting underwriting discounts and commissions and offering expenses payable by the Company and the Selling Securityholders.
A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.
A new study that appeared last Friday in British Medical Journal showed that one in three adults aged over 65 in England have difficulty understanding basic health-related information. They are more than twice as likely to die within five years as adults with no literacy problems, it was found.
With the help of 14 satellites currently in orbit and the National Aeronautics and Space Administration's (NASA) Applied Sciences Program, scientists have been able to observe the Earth's environment to help predict and prevent infectious disease outbreaks around the world.
› Verified 6 days ago
| Provider Name | Charles P Whitling |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1285784579 PECOS PAC ID: 3173719424 Enrollment ID: I20101129000283 |
News Archive
Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.
Neovasc Inc. is pleased to announce the closing of its previously announced underwritten public offering of 12,075,000 common shares of the Company at a price per share of US$7.19 (the "Offering") for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the Selling Securityholders (as defined below) before deducting underwriting discounts and commissions and offering expenses payable by the Company and the Selling Securityholders.
A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.
A new study that appeared last Friday in British Medical Journal showed that one in three adults aged over 65 in England have difficulty understanding basic health-related information. They are more than twice as likely to die within five years as adults with no literacy problems, it was found.
With the help of 14 satellites currently in orbit and the National Aeronautics and Space Administration's (NASA) Applied Sciences Program, scientists have been able to observe the Earth's environment to help predict and prevent infectious disease outbreaks around the world.
› Verified 6 days ago
| Provider Name | Jennifer A Yeselavage |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1407142771 PECOS PAC ID: 5698944064 Enrollment ID: I20110802000229 |
News Archive
Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.
Neovasc Inc. is pleased to announce the closing of its previously announced underwritten public offering of 12,075,000 common shares of the Company at a price per share of US$7.19 (the "Offering") for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the Selling Securityholders (as defined below) before deducting underwriting discounts and commissions and offering expenses payable by the Company and the Selling Securityholders.
A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.
A new study that appeared last Friday in British Medical Journal showed that one in three adults aged over 65 in England have difficulty understanding basic health-related information. They are more than twice as likely to die within five years as adults with no literacy problems, it was found.
With the help of 14 satellites currently in orbit and the National Aeronautics and Space Administration's (NASA) Applied Sciences Program, scientists have been able to observe the Earth's environment to help predict and prevent infectious disease outbreaks around the world.
› Verified 6 days ago
| Provider Name | Natalie M Boyce |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1083052286 PECOS PAC ID: 2567606031 Enrollment ID: I20130924000139 |
News Archive
Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.
Neovasc Inc. is pleased to announce the closing of its previously announced underwritten public offering of 12,075,000 common shares of the Company at a price per share of US$7.19 (the "Offering") for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the Selling Securityholders (as defined below) before deducting underwriting discounts and commissions and offering expenses payable by the Company and the Selling Securityholders.
A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.
A new study that appeared last Friday in British Medical Journal showed that one in three adults aged over 65 in England have difficulty understanding basic health-related information. They are more than twice as likely to die within five years as adults with no literacy problems, it was found.
With the help of 14 satellites currently in orbit and the National Aeronautics and Space Administration's (NASA) Applied Sciences Program, scientists have been able to observe the Earth's environment to help predict and prevent infectious disease outbreaks around the world.
› Verified 6 days ago
| Provider Name | Joseph N Giacometti |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1821232265 PECOS PAC ID: 1658593512 Enrollment ID: I20141107001389 |
News Archive
Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.
Neovasc Inc. is pleased to announce the closing of its previously announced underwritten public offering of 12,075,000 common shares of the Company at a price per share of US$7.19 (the "Offering") for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the Selling Securityholders (as defined below) before deducting underwriting discounts and commissions and offering expenses payable by the Company and the Selling Securityholders.
A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.
A new study that appeared last Friday in British Medical Journal showed that one in three adults aged over 65 in England have difficulty understanding basic health-related information. They are more than twice as likely to die within five years as adults with no literacy problems, it was found.
With the help of 14 satellites currently in orbit and the National Aeronautics and Space Administration's (NASA) Applied Sciences Program, scientists have been able to observe the Earth's environment to help predict and prevent infectious disease outbreaks around the world.
› Verified 6 days ago
| Provider Name | Emily A Jones |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1164872727 PECOS PAC ID: 2062705478 Enrollment ID: I20160722001113 |
News Archive
Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.
Neovasc Inc. is pleased to announce the closing of its previously announced underwritten public offering of 12,075,000 common shares of the Company at a price per share of US$7.19 (the "Offering") for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the Selling Securityholders (as defined below) before deducting underwriting discounts and commissions and offering expenses payable by the Company and the Selling Securityholders.
A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.
A new study that appeared last Friday in British Medical Journal showed that one in three adults aged over 65 in England have difficulty understanding basic health-related information. They are more than twice as likely to die within five years as adults with no literacy problems, it was found.
With the help of 14 satellites currently in orbit and the National Aeronautics and Space Administration's (NASA) Applied Sciences Program, scientists have been able to observe the Earth's environment to help predict and prevent infectious disease outbreaks around the world.
› Verified 6 days ago
| Provider Name | Alexa Golecki |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1902383599 PECOS PAC ID: 1557619301 Enrollment ID: I20180809006100 |
News Archive
Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.
Neovasc Inc. is pleased to announce the closing of its previously announced underwritten public offering of 12,075,000 common shares of the Company at a price per share of US$7.19 (the "Offering") for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the Selling Securityholders (as defined below) before deducting underwriting discounts and commissions and offering expenses payable by the Company and the Selling Securityholders.
A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.
A new study that appeared last Friday in British Medical Journal showed that one in three adults aged over 65 in England have difficulty understanding basic health-related information. They are more than twice as likely to die within five years as adults with no literacy problems, it was found.
With the help of 14 satellites currently in orbit and the National Aeronautics and Space Administration's (NASA) Applied Sciences Program, scientists have been able to observe the Earth's environment to help predict and prevent infectious disease outbreaks around the world.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Northeastern Eye Institute 200 Mifflin Ave, Scranton, PA 18503 Ph: (570) 342-3145 | Northeastern Eye Institute 200 Mifflin Ave, Scranton, PA 18503 Ph: (570) 342-3145 |
News Archive
Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.
Neovasc Inc. is pleased to announce the closing of its previously announced underwritten public offering of 12,075,000 common shares of the Company at a price per share of US$7.19 (the "Offering") for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the Selling Securityholders (as defined below) before deducting underwriting discounts and commissions and offering expenses payable by the Company and the Selling Securityholders.
A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.
A new study that appeared last Friday in British Medical Journal showed that one in three adults aged over 65 in England have difficulty understanding basic health-related information. They are more than twice as likely to die within five years as adults with no literacy problems, it was found.
With the help of 14 satellites currently in orbit and the National Aeronautics and Space Administration's (NASA) Applied Sciences Program, scientists have been able to observe the Earth's environment to help predict and prevent infectious disease outbreaks around the world.
› Verified 6 days ago
Mary Elizabeth Jordan-flickinger, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 200 Mifflin Ave, Scranton, PA 18503 Phone: 570-342-3145 Fax: 570-344-1309 | |
Miss Natalie M Boyce, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 200 Mifflin Ave, Scranton, PA 18503 Phone: 570-342-3145 Fax: 570-344-1309 | |
Dr. Megan Walsh, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 200 Mifflin Ave, Scranton, PA 18503 Phone: 570-342-3145 Fax: 570-343-3286 | |
Dr. Emily A Jones, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 200 Mifflin Ave, Scranton, PA 18503 Phone: 570-340-8053 | |
James Bradley Flickinger, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 200 Mifflin Ave, Scranton, PA 18503 Phone: 570-342-3145 Fax: 570-344-1309 | |
John W Boyle, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 3 W Olive St, Scranton, PA 18508 Phone: 570-558-5566 Fax: 570-558-3535 | |
Joseph F Cimochowski, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 200 Mifflin Ave, Scranton, PA 18503 Phone: 570-342-3145 Fax: 570-344-1309 |